Tag: Histogen Stock


Emricasan Found to be Safe and Well Tolerated from its Phase 1 Study Results Announced by Histogen (NASDAQ: HSTO) and Amerimmune

Histogen (NASDAQ: HSTO) opened its doors in 2007 after heeding to the call of a rising need to develop innovative technologies for aesthetic and therapeutic markets. The discovery by the company‚Äôs founder, Dr. Gail Naughton, of the potential of proteins and growth factors produced by cells grown under simulated embryonic […]